Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

SML1581

Sigma-Aldrich

Moxifloxacin hydrochloride

≥98% (HPLC)

Sinônimo(s):

12-8039, Avalox, BAY12-8039, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C21H24FN3O4· HCl
Número CAS:
Peso molecular:
437.89
Beilstein:
8377447
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77

Nível de qualidade

Ensaio

≥98% (HPLC)

forma

powder

atividade óptica

[α]/D -119 to -139°, c = 0.5 in water

condição de armazenamento

desiccated

cor

white to beige

solubilidade

H2O: 5 mg/mL, clear (warmed)

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

Cl.COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(O)=O

InChI

1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1

chave InChI

IDIIJJHBXUESQI-DFIJPDEKSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial. Moxifloxacin is a 8-methoxy quinolone and differs from other quinolones.

Aplicação

Moxifloxacin hydrochloride has been used to study its antibacterial action against bacteria that have grown to high density.

Ações bioquímicas/fisiológicas

Moxifloxacin has proved to be effective in treating sinusitis, community-acquired respiratory tract infection, pneumonia and acute exacerbations of chronic bronchitis. It has improved anti-gram positive activity compared to other fluoroquinolone such as ciprofloxacin and ofloxacin. Moxifloxacin is useful in treating skin infections that is of bacterial origin. It is known to have proper penetration into peripheral tissues and inflammatory fluids. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex. Compared to mammalian DNA gyrase, moxifloxacin has 100 times higher affinity for bacterial DNA gyrase. Moxifloxacin is an antibiotic and works against both Gram-positive and Gram-negative bacteria. Moxifloxacin is being investigated for the treatment of multidrug-resistant tuberculosis.

Pictogramas

Exclamation mark

Palavra indicadora

Warning

Frases de perigo

Classificações de perigo

Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Edward D Chan et al.
American journal of respiratory and critical care medicine, 169(10), 1103-1109 (2004-01-27)
Multidrug-resistant tuberculosis, a disease caused by Mycobacterium tuberculosis strains that are resistant at least to rifampin and isoniazid, entails extended treatment, expensive and toxic regimens, and higher rates of treatment failure and death. We retrospectively analyzed the outcomes in 205
An HPLC Method for the Determination of Moxifloxacin in Breast Milk by Fluorimetric Detection with Precolumn Derivatization.
Tekkeli SEK
Acta Chromatographica , 10-10 (2016)
Moxifloxacin.
Muijsers R B and Jarvis B
Drugs, 62(6), 967-973 (2002)
Stephen H Gillespie
European respiratory review : an official journal of the European Respiratory Society, 25(139), 19-28 (2016-03-02)
Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate
Francis S Mah
Current opinion in ophthalmology, 15(4), 316-320 (2004-07-03)
The fourth-generation fluoroquinolones, moxifloxacin and gatifloxacin, were introduced in 2003 promising improved spectrum of activity and delayed development of resistance. Although these topical agents have recently been introduced in commercial form, there is already a growing body of evidence showing

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica